ARCHIVES

FDA Approves Abraxane And Alimta for NSCLC

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011

Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study

January 28, 2011

ACS names new officers.

December 5, 2003

U. Arizona Center Finds a Way To Community Rapport

January 18, 1980

Weight Gain After Diagnosis Increases Risk Of Death

December 28, 2007

NRC Reports Says NIH Security Of nuclear Materials a Problem

January 5, 1996